Tyler Goodwin

Director/head Of Delivery Technologies (non-viral/viral Vectors/nucleic Acids/cmc/msat) at Tune Therapeutics

Tyler Goodwin, Ph.D. has a wealth of experience in gene and cell therapy. Tyler began their career in 2008 as an Undergraduate Research Scientist at the University of North Carolina Wilmington. Tyler then moved on to the University of North Carolina at Chapel Hill in 2013 as a Graduate Research Scientist. In 2016, they became a Scientific Consultant/Scientist, Non-Viral Gene Therapy at Qualiber, Inc. In 2017, they joined Precision BioSciences, Inc. as a Research and Development Scientist I (Gene Therapy Drug Products) and then as a Research and Development Scientist II (Gene Therapy Drug Products) and Cell Therapy Clinical Program CMC Lead. In 2020, they became a Senior Scientist Technical Lead (Gene Therapy Drug Products) at Kriya Therapeutics. In 2021, they joined BioTechLogic, Inc. as a Senior Technical Consultant (Cell and Gene Therapy). Currently, they are the Head of Delivery Development and Vector Core Technology/CMC/MSAT at Tune Therapeutics, where they are responsible for building the Gene Delivery team, establishing the Gene Delivery Vector Core, providing technical expertise and leadership guidance, and leading efforts to assess novel gene delivery technologies.

Tyler Goodwin, Ph.D. has an extensive educational background. Tyler obtained a Doctor of Philosophy (Ph.D.) in Pharmacoengineering and Molecular Pharmaceutics from the University of North Carolina at Chapel Hill. Prior to that, they earned a Master's Degree in Medicinal Chemistry from the University of North Carolina Wilmington and a Bachelor's Degree in Chemistry, with minors in Spanish and Math, from the same university. Additionally, they have obtained several certifications, including Crucial Accountability from Vital Smart (2020), Mini-MBA: Biopharma Innovation from Rutgers Business School (2020), Kepner and Tregoe (KT) Problem Solving and Decision Making from Kepner-Tregoe (2020), Team Leader Certification Program from CAI- Capital Associated Industries (2019), SAS JMP Design of Experiment (DOE) from SAS (2019), and Quality by Design (QbD) Training from the Biomanufacturing Education & Training Center (BETC), WPI (2019).

Location

Raleigh, United States

Links

Previous companies


Org chart


Teams

This person is not in any teams


Offices

This person is not in any offices


Tune Therapeutics

1 followers

With its versatile and powerful TEMPO epigenomic control platform, Tune Therapeutics is pioneering a new therapeutic modality that can fine-tune any gene network and unlock the full power and potential of regenerative medicine. With deep experience and a passionate commitment to exploration and innovation, Tune is driving through an inflection point in the history of genetic medicine: from targeting a limited range of rare conditions, to addressing thousands of common and complex diseases for which no curative treatment is available.


Employees

51-200

Links